MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

41.68 -1.28

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.59

Max

41.97

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-141M 3.1B
Eelmine avamishind	42.96
Eelmine sulgemishind	41.68

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. jaan 2026, 18:41 UTC

Tulu

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

24. jaan 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. jaan 2026, 09:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

24. jaan 2026, 06:18 UTC

Omandamised, ülevõtmised, äriostud

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23. jaan 2026, 22:30 UTC

Market Talk

Global Equities Roundup: Market Talk

23. jaan 2026, 22:30 UTC

Market Talk

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23. jaan 2026, 22:03 UTC

Tulu

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. jaan 2026, 21:52 UTC

Tulu

Omandamised, ülevõtmised, äriostud

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

23. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. jaan 2026, 21:39 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23. jaan 2026, 21:12 UTC

Tulu

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23. jaan 2026, 20:31 UTC

Tulu

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23. jaan 2026, 20:12 UTC

Market Talk

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23. jaan 2026, 20:07 UTC

Market Talk

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23. jaan 2026, 19:36 UTC

Market Talk

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23. jaan 2026, 19:30 UTC

Market Talk

Tulu

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23. jaan 2026, 19:18 UTC

Market Talk

Gold and Silver Step Up to More Records -- Market Talk

23. jaan 2026, 19:15 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

23. jaan 2026, 18:53 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

23. jaan 2026, 18:21 UTC

Tulu

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

23. jaan 2026, 18:19 UTC

Market Talk

Intel Seen as Increasingly Confident on Demand -- Market Talk

23. jaan 2026, 17:59 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

23. jaan 2026, 17:57 UTC

Market Talk

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

23. jaan 2026, 17:57 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

29.53% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD 29.53%

Kõrge 62 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.